| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6051259 | GENENTECH | Composition for sustained release of human growth hormone |
Dec, 2012
(11 years ago) | |
| US5656297 | GENENTECH | Modulated release from biocompatible polymers |
Jul, 2014
(9 years ago) | |
| US5654010 | GENENTECH | Composition for sustained release of human growth hormone |
Aug, 2014
(9 years ago) | |
Nutropin Depot is owned by Genentech.
Nutropin Depot contains Somatropin Recombinant.
Nutropin Depot has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Nutropin Depot are:
- US6051259
- US5656297
- US5654010
Nutropin Depot was authorised for market use on 22 December, 1999.
Nutropin Depot is available in injectable;injection dosage forms.
Nutropin Depot can be used as the long term treatment of growth failure due to lack of adequate endogenous growth hormone secretion in children.
The generics of Nutropin Depot are possible to be released after 05 August, 2014.
Drugs and Companies using SOMATROPIN RECOMBINANT ingredient
Market Authorisation Date: 22 December, 1999
Treatment: The long term treatment of growth failure due to lack of adequate endogenous growth hormone secretion in children
Dosage: INJECTABLE;INJECTION
NUTROPIN DEPOT family patents
